|
| Home : Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist |
|
Oct 22
2018 |
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist |
|
NEW HAVEN, Conn., Oct. 22, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that the first participant was dosed with BHV-3500, a third generation... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/biohaven-receives-authorization-to-proceed-from-fda-and-doses-first-subject-with-bhv-3500-third-generation-small-molecule-cgrp-receptor-antagonist-300734941.html |
| |
|
Related News
|
» OssDsign Announces FDA 510(k) Clearance of OSSDSIGN® Cranioplug
» SeraCare Announces Launch of Expanded NTRK Reference Material Panel
|
|
|
